Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. reports developments tied to its antibody discovery technology platform, partner pipeline and licensing model. The company licenses discovery research technology to pharmaceutical, biotechnology and academic partners, using engineered transgenic animals, Biological Intelligence™, computational antigen design, immunization methods, high-throughput single B-cell screening and sequencing-data mining to identify human antibody and target-binding protein candidates.
Recurring news includes quarterly financial results, partner program updates, new license agreements, milestone and royalty revenue, and technology launches such as OmniUltra™ and the xPloration® partner access program. Company updates also cover clinical and commercial progress of OmniAb-derived partnered programs, investor conference participation and corporate presentations focused on antibody discovery applications.
OmniAb (NASDAQ: OABI) will participate at the Leerink Global Healthcare Conference March 8-11, 2026, in Miami. Management will present a corporate overview on Tuesday, March 10, 2026 at 3:40 p.m. ET and will hold one-on-one investor meetings for registered attendees.
Investors should contact their Leerink Partners representative or email LeerinkEvents@Leerink.com to schedule meetings.
OmniAb (NASDAQ: OABI) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, March 4, 2026 and will host a conference call the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific. A live webcast with slides and a replay will be available.
Telephone access includes U.S. and international dial-in numbers; Conference ID is 62412.
OmniAb (NASDAQ: OABI) launched OmniUltra on December 15, 2025, described as the industry’s first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
OmniUltra generates human immune repertoires with cow-inspired ultralong CDRH3s and isolates picobodies™ (4–6 kDa), enabling antibodies and peptide therapeutics for bispecifics, CAR-T, radioligands and standalone peptides. The company presented at AET 2025 and will host a Virtual Investor Event today at 5:00 p.m. ET with slides and a replay on its investor site.
OmniAb (NASDAQ: OABI) will host a virtual investor event to unveil OmniUltra on Monday, December 15, 2025 at 5:00 p.m. ET (2:00 p.m. PT). The event is expected to run about one hour and will feature management's overview of OmniUltra, described as a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
Topics include the technology platform, market use and applications, and its strategic importance. A live webcast with slides and a replay will be available, and U.S. and international dial-in numbers are provided (Conference ID 44666).
OmniAb (NASDAQ: OABI) entered a technology license and services agreement with Mabtrx Biosciences, a newly formed ArrowMark–Viking joint venture, announced on November 17, 2025. The agreement covers OmniAb-derived antibody discovery programs and obligates OmniAb to provide discovery services to Mabtrx.
Under the deal OmniAb will receive revenue for services performed and is eligible for potential equity and royalties tied to discovery of novel antibodies for targets defined by Mabtrx. Management highlighted the use of OmniAb’s transgenic chicken–based technologies to support the collaboration.
OmniAb (NASDAQ: OABI) reported third quarter 2025 results on November 4, 2025: Q3 revenue $2.2M versus $4.2M year-ago and Q3 net loss $16.5M ($0.14/share). Nine-month revenue was $10.3M and nine-month net loss was $50.6M ($0.46/share).
The company ended September 30, 2025 with $59.5M in cash and equivalents after an August private placement that raised $30M (~$28M net). 2025 guidance: revenue $18–22M, operating expense $82–86M, year-end cash expected $52–56M. OmniAb reported 104 active partners, 399 active programs and 32 programs in clinical development or commercialization; OmniUltra™ launch planned for December 2025.
OmniAb (NASDAQ: OABI) announced management participation in three investor conferences in November 2025. Key events:
- Truist Securities BioPharma Symposium — November 6, Lotte New York Palace Hotel; Matt Foehr, CEO, will hold one-on-one investor meetings.
- Stifel Healthcare Conference — November 11-13, Lotte New York Palace Hotel; Kurt Gustafson, CFO, will hold one-on-one investor meetings on November 12.
- Jefferies Global Healthcare Conference — London — November 17-20, Waldorf Hilton; Matt Foehr will present a corporate overview on November 19 at 8:00 a.m. GMT and hold meetings on November 18-19.
The schedule highlights management access to investors via presentations and one-on-one meetings across U.S. and London industry conferences.
OmniAb (NASDAQ: OABI) will report third quarter 2025 financial results for the three and nine months ended September 30, 2025 after U.S. market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day beginning at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and business updates.
Participants can join by phone (U.S. dial-in (800) 549 8228; international (646) 564 8277; Conference ID 92631). A live webcast and replay with slides will be available via the company’s webcast link.
OmniAb (NASDAQ: OABI) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. The company's management team will be available for one-on-one meetings with registered investors on September 9, 2025.
Interested investors can schedule meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.
OmniAb (NASDAQ: OABI) has announced a private placement to raise approximately $30 million through the sale of 21,254,106 shares of common stock. The shares will be priced at $1.40 per share, with officer and director participants paying $1.85 per share.
The placement, expected to close around August 26, 2025, includes participation from top-tier new and existing investors, along with company officers and directors. Leerink Partners is serving as the sole placement agent. The proceeds will be used for general corporate purposes, and OmniAb will file a registration statement with the SEC for the resale of these shares.